Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at 11 dose levels between 9 mg m(−2) d(−1) and the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, C J, Gardner, C, Flavin, A, Sludden, J, Dennis, I, Bono, J de, Beale, P, Vasey, P, Hutchison, C, Macham, M A, Rodriguez, A, Judson, I, Bleehen, N M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363132/
https://www.ncbi.nlm.nih.gov/pubmed/10468297
http://dx.doi.org/10.1038/sj.bjc.6690598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363132/
https://www.ncbi.nlm.nih.gov/pubmed/10468297
http://dx.doi.org/10.1038/sj.bjc.6690598

Ejemplares similares